Current NHS status
As of February 2026, Mounjaro (tirzepatide) is approved and available on the NHS for the treatment of type 2 diabetes. NICE published positive guidance (TA924) recommending tirzepatide as an option for managing blood sugar levels in adults with type 2 diabetes when other treatments are insufficient. However, Mounjaro is not yet routinely available on the NHS specifically for weight management. The distinction is important: if you have type 2 diabetes, your GP or specialist may be able to prescribe Mounjaro on the NHS. If your primary goal is weight loss and you do not have type 2 diabetes, you will currently need to access it through a private prescription.
What NICE says
NICE is the body that evaluates medications and determines whether they should be available on the NHS in England and Wales. For type 2 diabetes, NICE has already recommended tirzepatide. For obesity and weight management (without type 2 diabetes), NICE is continuing to evaluate the evidence. The appraisal process considers clinical effectiveness, cost-effectiveness compared to existing treatments, and the budget impact on the NHS. Previous NICE decisions on weight management medications (such as approving semaglutide for weight management) suggest that tirzepatide may eventually receive similar approval, but the timeline remains uncertain. NICE appraisals can take 12-24 months, and there may be additional conditions or restrictions on who qualifies.
When might Mounjaro be available for weight loss on the NHS?
There is no confirmed date for when Mounjaro will become available on the NHS for weight management. Based on the NICE appraisal timeline and the progression of similar evaluations, it is possible that a decision could come in 2026 or 2027, but this is speculative. Even once NICE issues guidance, NHS roll-out is not immediate. Factors that could affect availability include NHS funding decisions, supply chain capacity, the development of specialist weight management services to prescribe and monitor the medication, and whether any restrictions are placed on eligibility criteria (for example, minimum BMI thresholds or requirements to have tried other interventions first). It is also worth noting that even when a medication is approved for NHS use, access can vary by region and local commissioning decisions.
The private route alternative
While waiting for potential NHS availability, the private prescription route remains the main way to access Mounjaro for weight management in the UK. This involves consulting with a registered prescriber through a private online pharmacy or weight management clinic. The process is straightforward: you complete a health assessment, a prescriber reviews your suitability, and if approved, the medication is dispatched to you with cold-chain delivery. You do not need a GP referral, although informing your GP is recommended. Tens of thousands of people in the UK are currently using Mounjaro through private prescriptions. The market is well-established, with over 60 GPhC-registered pharmacies offering the service. For a detailed walkthrough of how the process works, see our guide on how to get Mounjaro in the UK.
Cost of private Mounjaro
The cost of Mounjaro through private prescription ranges from approximately £130 to £320 per month, depending on the dose and pharmacy. The starting dose (2.5mg) is typically the cheapest, with prices increasing for higher doses. The price difference between pharmacies can be substantial. For example, two GPhC-registered pharmacies might charge £149 and £229 respectively for the same 5mg dose, a difference of £80 per month or nearly £1,000 per year. This is why price comparison is so valuable. You can use our comparison table to check current prices across all pharmacies and find the best deal for your dose. Some pharmacies also offer subscription plans, bundle deals, or loyalty pricing that can reduce the long-term cost.
How to check if you are eligible
Whether you access Mounjaro through the NHS (for type 2 diabetes) or privately (for weight management), you will need to meet certain eligibility criteria. For NHS prescribing for type 2 diabetes, your GP or specialist will assess whether tirzepatide is appropriate based on NICE guidelines, your current diabetes management, and other medications you take. For private weight management prescriptions, the typical eligibility criteria include:
- BMI of 30 or above, OR BMI of 27 or above with at least one weight-related health condition (such as high blood pressure, high cholesterol, type 2 diabetes, or sleep apnoea)
- Age 18 or over
- Not pregnant, breastfeeding, or planning to become pregnant
- No personal or family history of medullary thyroid carcinoma or MEN 2
- No history of pancreatitis
- Previous attempts at weight management through diet and exercise